Zhitong Finance App News, Shiyao Group (01093.HK) issued an announcement. The Class 1 recombinant shingles vaccine (SYS 6052), a new prophylactic biological product developed by the Group, has been approved by the US Food and Drug Administration (FDA) and can carry out related clinical research in the US. Previously, the product was approved by China's National Drug Administration (NMPA) to conduct clinical trials in China in July 2026.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Shiyao Group (01093.HK) issued an announcement. The Class 1 recombinant shingles vaccine (SYS 6052), a new prophylactic biological product developed by the Group, has been approved by the US Food and Drug Administration (FDA) and can carry out related clinical research in the US. Previously, the product was approved by China's National Drug Administration (NMPA) to conduct clinical trials in China in July 2026.